Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Gerger, A; El-Khoueiry, A; Zhang, W; Yang, D; Singh, H; Bohanes, P; Ning, Y; Winder, T; Labonte, MJ; Wilson, PM; Benhaim, L; Paez, D; El-Khoueiry, R; Absenger, G; Lenz, HJ.
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Clin Cancer Res. 2011; 17(17):5783-5792 Doi: 10.1158/1078-0432.CCR-11-1115 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Leading authors Med Uni Graz: Gerger Armin
Co-authors Med Uni Graz: Absenger Gudrun
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Purpose: There is substantial germline genetic variability within angiogenesis pathway genes, thereby causing interindividual differences in angiogenic capacity and resistance to antiangiogenesis therapy. We investigated germline polymorphisms in genes involved in VEGF-dependent and -independent angiogenesis pathways to predict clinical outcome and tumor response in metastatic colorectal cancer (mCRC) patients treated with bevacizumab and oxaliplatin-based chemotherapy. Experimental Design: A total of 132 patients treated with first-line bevacizumab and FOLFOX or XELOX were included in this study. Genomic DNA was isolated from whole-blood samples by PCR-RFLP or direct DNA sequencing. The endpoints of the study were progression-free survival (PFS), overall survival (OS), and response rate (RR). Results: The minor alleles of EGF rs444903 A>G and IGF-1 rs6220 A>G were associated with increased OS and remained significant in multivariate Cox regression analysis (HR: 0.52; 95% CI: 0.31-0.87; adjusted P = 0.012 and HR: 0.60; 95% CI: 0.36-0.99; adjusted P = 0.046, respectively). The minor allele of HIF1 alpha rs11549465 C>T was significantly associated with increased PFS but lost its significance in multivariate analysis. CXCR1 rs2234671 G>C, CXCR2 rs2230054 T>C, EGFR rs2227983 G>A, and VEGFR-2 rs2305948 C>T predicted tumor response, with CXCR1 rs2234671 G>C remaining significant in multiple testing (Pact 0.003). Conclusion: In this study, we identified common germline variants in VEGF-dependent and -independent angiogenesis genes predicting clinical outcome and tumor response in patients with mCRC receiving first-line bevacizumab and oxaliplatin-based chemotherapy. Clin Cancer Res; 17(17); 5783-92. (C)2011 AACR.
Find related publications in this database (using NLM MeSH Indexing): Adult -; Aged -; Aged, 80 and over -; Alleles -; Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - pharmacology Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal, Humanized - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemokines - genetics; Colorectal Neoplasms - blood supply Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics; Cytokines - genetics; Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use; Disease-Free Survival -; Female -; Fluorouracil - analogs & derivatives Fluorouracil - therapeutic use; Genetic Variation -; Genotype -; Humans -; Leucovorin - therapeutic use; Male -; Middle Aged -; Neovascularization, Pathologic - drug therapy Neovascularization, Pathologic - genetics; Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - therapeutic use; Pharmacogenetics -; Polymorphism, Restriction Fragment Length -; Polymorphism, Single Nucleotide -; Vascular Endothelial Growth Factor A - genetics